Report: Surging Bispecific ADC Trials Eye FDA Approval 2025
In early clinical testing for esophageal squamous cell carcinoma, the bispecific ADC izalontamab brengitecan reported a confirmed objective response...
Jon Napitupulu
Kyverna Spotlights New CAR T Trial for Myasthenia Gravis
Kyverna outlined a registrational path for KYV-101 in generalized myasthenia gravis (MG), converting its KYSA-6 study into a Phase...
Zevra to Unveil Multiple Arimoclomol Datasets at ICIEM Meet
In its pivotal Phase 3 study, arimoclomol (MIPLYFFA) halted disease progression versus placebo over 12 months on the NPC...
Aavantgarde Presents Updated LUCE-1 Data at Euretina 2025
No new efficacy or safety numbers were disclosed. Still, AAVantgarde Bio will present updated Phase 1/2 LUCE-1 data for...
Anavex Publishes Blarcamesine Autophagy Study Results
Anavex Life Sciences has published preclinical data in •iScience• further elucidating the mechanism by which its SIGMAR1 (S1R) agonist,...
Incannex Reports Positive Phase 2 Trial Results for Generalized Anxiety Disorder
Incannex Healthcare’s Phase 2 trial of PSX-001 (formerly Psi-GAD), a psilocybin-assisted therapy for generalized anxiety disorder (GAD), demonstrated statistically...
Marker Therapeutics Reports Encouraging Response Rates in Lymphoma Study
Marker Therapeutics’ Phase 1 APOLLO study of MT-601 in relapsed B-cell lymphoma patients yielded a 66% objective response rate...
Regeneron’s Phase 3 Trial Shows Positive Results in Myasthenia Gravis
Cemdisiran monotherapy, administered subcutaneously every three months, demonstrated a 2.3-point placebo-adjusted improvement in the Myasthenia Gravis Activities of Daily...
BioXcel Therapeutics Announces Topline Results from Phase 3 Trial of Igalmi
BioXcel Therapeutics’ BXCL501, a sublingual dexmedetomidine film, met its primary endpoint of tolerability in the SERENITY At-Home Phase 3...
Telitacicept Succeeds in Phase 3 IgA Nephropathy Trial
In Stage A of a Phase 3 trial in China, RemeGen’s telitacicept achieved a 55% reduction in 24-hour urine...